Home > Genisphere Develops a Universal Signal Amplification Process for Lateral Flow Rapid Test Applications
News & Events

Genisphere Develops a Universal Signal Amplification Process for Lateral Flow Rapid Test Applications

October 7, 2013 -

Genisphere LLC reported today it has adapted its 3DNA® Nanotechnology for use as a universal signal amplification system for improving the sensitivity and overall performance of rapid diagnostic tests and applications. Detailed in a patent application submitted on August 16th, the new process is a further enhancement of the 3DNA® Signal Amplification technology, and eliminates the need for custom chemical modification of antibodies when combined with 3DNA® signal amplifiers and used as detection reagents in lateral flow rapid immunoassays.

“It’s well known that sensitivity is a major driver of commercial success and value for point-of- care tests”, said Jim Kadushin, Genisphere’s Chief Operating Officer. “Genisphere’s new process for combining analyte-specific antibodies with 3DNA® signal amplifiers will streamline the development of more sensitive tests and reduce costs to address the highly competitive rapid diagnostics market.”

Genisphere’s 3DNA® Nanotechnology has been used to improve the performance of a variety of assay platforms for protein and nucleic acid detection, including microarrays, ELISAs, bead- based flow cytometry, and most recently, lateral flow rapid tests. The 3DNA® reagent provides up to 100-fold improvement in sensitivity without increasing the assay’s complexity. This improved performance enables point-of-care analyses that have not previously been possible with conventional systems.

“Genisphere is partnering with key successful players in fast growing markets,” said Bob Getts, Genisphere’s Chief Science Officer. “We believe our new proprietary process provides more flexibility and a faster-to-market path for companies interested in collaborating with Genisphere to improve the performance of their existing products or assays still in the R&D pipeline.”

About Genisphere

Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA® nanotechnology. For more information, please visit http://genisphere.com.

For more information contact:

Tom Bliss
CEO, Genisphere